Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Abstract Text:

Qing Ma,Mahmut Tobu,Christopher Schultz,Walter Jeske,Debra Hoppensteadt,Jeanine Walenga,Umberto Cornelli,John Lee,Robert Linhardt,Israel Hanin,Jawed Fareed,Qing Ma,Mahmut Tobu,Christopher Schultz,Walter Jeske,Debra Hoppensteadt,Jeanine Walenga,Umberto Cornelli,John Lee,Robert Linhardt,Israel Hanin,Jawed Fareed,

Heparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. We compared the influence of molecular weight on the TFPI release by heparin and its fractions in a non-human primate model. Primates were treated with unfractionated heparin, a low molecular weight heparin (gammaparin), or a heparin-derived oligosaccharide mixture (C3). Endothelial TFPI release was determined using both immunologic and functional assays. After intravenous administration, all agents significantly increased TFPI levels (p<0.05) in a dose dependent manner. The increase produced by unfractionated heparin and gammaparin was greater than that by C3 at an equal dosage (p<0.05). With subcutaneous injection, all agents produced less TFPI release. Repeated administration of heparin-derived oligosaccharides gradually increased TFPI release. A 1.89 fold increase in TFPI levels was observed 4 days after C3 treatment (2.5 mg/kg). Our findings indicated that TFPI release is dependent on the molecular weight of heparin and its derivatives. Heparin oligosaccharides exert their vascular effects through increased TFPI release after long-term repeated administration.

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Publishing Authors By Initials

Q Ma,M Tobu,C Schultz,W Jeske,D Hoppensteadt,J Walenga,U Cornelli,J Lee,R Linhardt,I Hanin,J Fareed,Q Ma,M Tobu,C Schultz,W Jeske,D Hoppensteadt,J Walenga,U Cornelli,J Lee,R Linhardt,I Hanin,J Fareed,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Thrombosis research

VOLUME: 119

Page Numbers: 653-61

Journal Abbreviation: Thromb. Res.

ISSN: 0049-3848

DAY: 7

MONTH: 07

YEAR: 2006

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 326377

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

AFFILIATION: Department of Pharmacology and Experimental Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA. qingma@buffalo.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Thromb Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides Related Publications

• Cardiovascular diseases as a cause of death in the island of Mauritius, 1972-1980.
• Contaminant in the Recalled Unfractionated Heparin Preparations: Where is the Problem?
• Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.
• Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
• Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step.
• Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
• Laboratory evaluation of the antiphospholipid syndrome.
• Laboratory monitoring of the clinical effects of low molecular weight heparins.
• Management of deep vein thrombosis.
• Methicillin resistant Staphylococcus aureus: a multicentre study.
• Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.
• Pattern of malarial infection diagnosed at Ayub Teaching Hospital Abbottabad.
• Problem-based learning variant: transition phase for a large institution.
• The future of anticoagulation.